Clinical Trial Update: T- XELOX in HER2-positive Stage III Gastric Cancer After D2 Gastrectomy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating trastuzumab plus XELOX (capecitabine and oxaliplatin) in HER2-positive stage III gastric cancer after D2 gastrectomy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Eloxatin (oxaliplatin)
• HERCEPTIN (trastuzumab)

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Gastric Cancer | Phase 2 | Status: UNKNOWN